Ubs Group AG Schedule 13G passive stakes

UBS Group AG has filed an amended Schedule 13G, indicating it no longer beneficially owns any common stock of PIMCO Access Income Fund as of March 31, 2025.

UBS Group AG has filed an amended Schedule 13G, indicating it no longer holds a reportable beneficial ownership stake in Color Star Technology Co., Ltd.

UBS Group AG has reported a beneficial ownership of 5.8% in Western Asset Investment Grade Opportunity Trust Inc., holding 345,414 shares as of March 31, 2025.

UBS Group AG has filed an amended Schedule 13G, reporting a 44.3% beneficial ownership stake in abrdn Income Credit Strategies Fund's 5.250% Series A Perpetual Preferred Shares as of March 31, 2025.

UBS Group AG has filed an amended Schedule 13G, indicating it no longer beneficially owns any common stock of Infinera Corp as of March 31, 2025.

UBS Group AG has filed an amendment to its Schedule 13G, indicating it no longer holds a reportable beneficial ownership stake in The Clorox Company as of March 31, 2025.

UBS Group AG has disclosed a beneficial ownership of 8.15% in Clorox Co., totaling 10,084,448 shares, as of December 31, 2024, clarifying a previous administrative inclusion.

Norges Bank, acting on behalf of the Government of Norway, has filed an amended Schedule 13G disclosing a 4.0% passive beneficial ownership stake in UBS Group AG as of March 31, 2025.

UBS Group AG has filed an amended Schedule 13G, revealing a beneficial ownership of 18.3% of Vipshop Holdings Ltd's Class A ordinary shares, totaling 15,943,270 shares, as of December 31, 2024.

UBS Group AG has filed an amended Schedule 13G, reporting a beneficial ownership of 5.05% in PIMCO Access Income Fund's Common Stock as of December 31, 2024.

UBS Group AG has disclosed a 5.06% beneficial ownership stake in Renalytix plc, holding 16,774,708 ordinary shares, primarily due to its acquisition of Credit Suisse Group AG.

UBS Group AG has filed an amended Schedule 13G, reporting 0% beneficial ownership in Liberty Broadband Corp's Series C common stock following its acquisition of Credit Suisse Group AG.

UBS Group AG has filed an amended Schedule 13G for Amneal Pharmaceuticals, Inc., reporting zero beneficial ownership of Class A Common Stock as of December 31, 2024, following its acquisition of Credit Suisse Group AG.

UBS Group AG has filed a Schedule 13G, revealing a 7.09% beneficial ownership stake in Color Star Technology Co., Ltd.'s Class A Ordinary Shares as of December 31, 2024.